Europe can achieve herd immunity against coronavirus within the next four months, according to the head of German pharmaceutical company BioNTech.
The company developed the first widely approved Covid-19 vaccine with US partner Pfizer.
While the exact threshold required to reach that critical level of immunisation remains a matter of debate, experts say a level above 70% would significantly disrupt transmission of coronavirus within a population.
"Europe will reach herd immunity in July, latest by August," said Ugur Sahin, BioNTech's chief executive.
His company's Covid-19 vaccine makes up a large share of the doses administered in Europe and North America, where it is more commonly known as the Pfizer shot.
Mr Sahin said data from people who have received the vaccine show that the immune response gets weaker over time, and a third shot will probably be required.
Studies show the efficacy of the BioNTech/Pfizer vaccine declines from 95% to about 91% after six months, he said.
"Accordingly, we need a third shot to get the vaccine protection back up to almost 100% again" Mr Sahin said.
He suggested this should be administered nine to 12 months after the first shot.
"And then I expect it will probably be necessary to get another booster every year or perhaps every 18 months again," he said.
Concerns have been raised that existing vaccines might be less effective against new variants of the virus now emerging in different parts of the world.
Mr Sahin said BioNTech has tested its vaccine against more than 30 variants, including the now-dominant one first detected in Britain, and found the shot triggers a good immune response against almost all of them in the lab. In cases where the immune response was weaker, it remained sufficient, he said, without providing exact figures.
Asked about the new variant first detected in India, Mr Sahin said the vaccine's effectiveness against it was still being investigated.
"But the Indian variant has mutations that we have previously investigated and against which our vaccine also works, so I am confident there, too," he said.
The Mainz-based company's work developing a vaccine based on messenger RNA, or mRNA, benefited from its earlier research into pharmaceuticals to treat cancer, as tumours often try to adapt to evade the immune system, Mr Sahin said.
"The way our vaccine works is that it has two points of attack," he explained. Along with stimulating the production of antibodies, it prompts the body's so-called T-cells to attack the virus, he said.
"The vaccine is quite cleverly constructed, and the bulwark will hold. I'm convinced of that," Mr Sahin said. "If the bulwark needs to be strengthened again, we'll do so. I'm not worried."
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here